Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer’s Disease or Behavioral Variant Frontotemporal Dementia (NCT02245568) (2017)

Government Record · TauRx Therapeutics Ltd (sponsor); ClinicalTrials.gov record · May 2017

TauRx Therapeutics Ltd (sponsor), 2017-05: Open-label extension providing continued LMTM access to 913 patients from the phase 2 and phase 3 programme; terminated in May 2017 for administrative reasons only. Results were first posted on the registry on 2 June 2020.

The purpose of this study is to provide subjects who have completed participation in a Phase 2 or Phase 3 trial of LMTM continued access to therapy and to evaluate the long-term safety of LMTM.

TauRx Therapeutics Ltd (sponsor), 2017-05: Open-label extension providing continued LMTM access to 913 patients from the phase 2 and phase 3 programme; terminated in May 2017 for administrative reasons only. Results were first posted on the registry on 2 June 2020. Record fields transcribed from ClinicalTrials.gov API v2 (briefSummary, overallStatus, whyStopped, enrollmentInfo, primaryCompletionDate). Registry status TERMINATED; whyStopped text quoted. Long-term safety data from this 913-patient extension are not posted on the registry. hosting=LINK because the ClinicalTrials.gov study record is HTML-only (no PDF); copyright remains US Federal Public Domain. The record text was read from https://clinicaltrials.gov/api/v2/studies/NCT02245568 and the study page is JavaScript-rendered. Also filed as MTK-47 (claims C14, C9).